Curaleaf International Announced as Headline Partner for Cannabis Europa Conference in London
London, UK – March 21, 2024 – Curaleaf International, a leading global cannabis company, has been announced as the Headline Partner for the highly anticipated Cannabis Europa conference, set to take place in London on 25-26 June, 2024.
Cannabis Europa is the premier conference series in Europe that brings together influential leaders in science, policy, and business to build a responsible and effective European cannabis industry. With a focus on innovation, regulation, and investment opportunities, the conference serves as a platform for collaboration and progress in the rapidly evolving cannabis industry.
As the Headline Partner for Cannabis Europa, Curaleaf International brings its unparalleled expertise and commitment to advancing the medical cannabis industry in Europe. With a strong emphasis on research and scientific rigor, Curaleaf International sets the standard for the industry and is on a rapid growth trajectory.
According to Prohibition Partners’ European Cannabis Report: 8th Edition, Europe’s medical cannabis market is projected to reach €2.2 billion and serve 1.5 million patients by 2027.
“We are thrilled to partner with Cannabis Europa for this groundbreaking event,” said Juan Martinez, Head of Curaleaf International. “As a global leader in the cannabis industry, we are dedicated to driving positive change and shaping the future of the industry. Cannabis Europa provides an invaluable platform for collaboration, innovation, and education, and we look forward to contributing to meaningful discussions and insights at the conference.”
Stephen Murphy, co-founder and CEO of Cannabis Europa and Prohibition Partners, also expressed excitement about the partnership. “Since 2018, Cannabis Europa has been the premier destination for industry and policy leaders to come together and shape the future of cannabis. We are delighted to welcome Curaleaf International as the Headline Partner for this year’s Cannabis Europa conference in London. As a global leader in the cannabis industry, Curaleaf International is driving positive change in healthcare and setting the standards for this emerging industry.”
The two-day conference in London will feature a diverse lineup of speakers, including industry experts, policymakers, healthcare professionals, and investors. They will discuss a variety of topics, such as medical advancements, regulatory frameworks, investment opportunities, and global market trends.
For more information about Cannabis Europa and to register for the conference, please visit the official website at www.cannabis-europa.com.
For media inquiries or interview requests, please contact:
Mike Hoban
Head of Marketing & Communications
Prohibition Partners
+44(0)7841 697 433
michael@prohibitionpartners.com
About Cannabis Europa
Cannabis Europa is a conference series that connects influential leaders in science, policy, and business to build a responsible and effective European cannabis industry that promotes innovation, access, and growth. Their events serve as a catalyst for political change and a platform for cannabis-related businesses to connect with mainstream brands.
The inaugural Cannabis Europa conference took place in 2018 at the Barbican in London. Within a month, the Home Office acknowledged the medical benefits of cannabis and began to review their stance on its use as medicine, paving the way for patient access. Since then, Cannabis Europa has continued to drive progress and shape the future of cannabis, hosting industry-leading conferences in Paris (2019), London (2019), Toronto (2019), New York (2019), Madrid (2020), and London (2021, 2022, 2023).
About Curaleaf International
Curaleaf International is one of the largest vertically integrated cannabis companies in Europe. Their unique supply and distribution network throughout the European market brings together pioneering science and research with cutting-edge cultivation, extraction, and production. With a strong emphasis on quality and expertise, Curaleaf International aims to deliver safe, reliable, and effective care to all their patients.
Curaleaf International’s subsidiaries include Curaleaf Clinic, Curaleaf Pharmacy, and Curaleaf Laboratories within the UK, as well as Terra Verde cultivation facility in Portugal, Medalchemy research and development site in Spain, Four20 Pharma wholesaler and distributor in Germany, and the Polish wholesaler Can4Med.
Curaleaf International is a subsidiary of Curaleaf Holdings, Inc., a leading global cannabis company. They are listed on the TSX (Toronto Stock Exchange) and trade on the OTCQX market under the symbol CURLF.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.